Industry & Business

Pretax losses double at Dublin-listed Merrion Pharmaceuticals

 Breaking News
  • Fáilte Ireland Crafts a New Path to Success Across Ireland’s Ancient East Fáilte Ireland has unveiled a bespoke toolkit to equip and train craft businesses across Ireland’s Ancient East with the skills to maximise the potential of craft tourism to generate increased revenue and support local jobs. John Paul Phelan TD, Minister of State for Local Government and Electoral Reform, officially launched the Fáilte Ireland toolkit at Kilkenny’s Jerpoint Glass – a [...]...
  • Property Market Grows 8% – Almost Half of Homes Bought With Cash The latest quarterly Consumer Market Monitor (CMM), published by the Marketing Institute of Ireland and UCD Michael Smurfit Graduate Business School, shows slow but steady growth in Ireland’s residential property market, with 55,000 homes purchased in 2018, an increase of just 8% on the previous year. Excluding mortgages from the 2018 figures, there were almost 25,000 [...]...
  • Kerry Group Benefits From Unique Business Model Kerry Group, the global taste, nutrition and consumer foods business, has reported a 3.1% increase in revenue to €6.6 billion for the year ended 31 December 2018, reflecting strong volume growth and contribution from acquisitions, partially offset by adverse currency movements. Business volumes grew by 3.5% and pricing decreased by 0.5% against a backdrop of [...]...
  • 30% Increase in Dublin Industrial Take-up Dublin industrial take up for 2018 totalled 3.3 million sq ft which is a 31% increase on last year. Whilst activity was dominated by smaller deals, take-up totals were boosted by a number of larger-sized deals. There were 14 deals greater than 50,000 sq ft in the last 12 months. The top 5 deals this [...]...
  • Skillnet Ireland Wins Big at Top Digital Awards 2019 Skillnet Ireland, the national agency responsible for the promotion and facilitation of workforce learning, won big at the recent 2019 Digital Media Awards , picking up the award for Best Brand. Other finalists in the ‘Best Brand’ category included Diet Coke, BMW, Thérapie Clinic and 98FM. Established in 2005, the Digital Media Awards are the most [...]...

Pretax losses double at Dublin-listed Merrion Pharmaceuticals

Pretax losses double at Dublin-listed Merrion Pharmaceuticals
October 02
09:19 2015

Merrion Pharmaceuticals says its survival is dependent on Declan Ryan’s Irelandia Investments not calling in an overdue loan as it reported a doubling of half-year losses.

The Dublin-listed group, whose Irish revenue comes through two licence agreements with Danish diabetes specialist Novo Nordisk, reported a net loss of €1.02 million or €5.58 cent per share for the six months to the end of June. This compares to a loss of €507,000 or €2.76 cents for the same period a year earlier.

The decline was largely due to a €705,000 drop in revenue from €955,793 to €250,000.

For the same period last year, Merrion’s revenues were boosted by a €727,000 milestone payment from Novo Nordisk on completion of a single dose Phase 1 trial with a novel oral insulin.

Administrative and research and development declined by €440,000 from €1 million to €561,000 from June 2014 to the same month this year. Net finance expenses rose by €276,000 from €454,000 to €716,000 over the same period, due in part to foreign exchange losses.

Established in 2003, Merrion is engaged in developing oral forms of drugs that typically have poor absorption and are generally given by injection.

In its interim statement the group said its ability to generate sufficient cash to repay a €4.8 million loan to Irelandia “cast significant doubt on the ability of the group to continue as a going concern for the foreseeable future.”

Repayment of the loan was originally due to be made in December. At the end of March Irelandia agreed to extend the principal repayment term by 18 months to the end of September with the deferred interest of €167,569 remaining payable aby June 30th. It has since said though that it has no intention of calling in repayment of the laon before the end of this year.

Merrion said that notwithstanding the uncertainty over the loan repayment its directors had a “reasonable expectation that the group has adequate resources to continue in operational existence for the foreseeable future.”

Chairman Michael McKenna said the company continues to be encouraged by the success of Novo Nordisk in employing Merrion’s technology in the development of treatment of diabetes using oral medication.

About Author



Related Articles

New Subscriber

Subscribe Here


National Manufacturing Conference & Exhibition 2018

NIBRT Springboard Success Stories

Upcoming Events

  • No upcoming events
AEC v1.0.4